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ABSTRACT Severe acute liver injury due to acci-
dental or intentional acetaminophen overdose pre-
sents a major clinical dilemma often requiring liver
transplantation. In the present study, liver regenera-
tion after profound liver injury in mice challenged
with acetaminophen was facilitated by the exogenous
addition of ELR-containing CXC chemokines such as
macrophage inflammatory protein-2 (MIP-2), epithe-
lial neutrophil-activating protein-78 (ENA-78), or in-
terleukin 8. Intravenous administration of ELR-CXC
chemokines or N-acetyl-cysteine (NAC) immediately
after acetaminophen challenge in mice significantly
reduced histological and biochemical markers of
hepatic injury. However, when the intervention was
delayed until 10 h after acetaminophen challenge,
only ELR-CXC chemokines significantly reduced
liver injury and mouse mortality. The delayed addi-
tion of ELR-CXC chemokines to cultured hepato-
cytes maintained the proliferation of these cells in a
CXCR2-dependent fashion after acetaminophen
challenge whereas delayed NAC treatment did not.
These observations demonstrate that ELR-CXC
chemokines represent novel hepatic regenerative
factors that exhibit prolonged therapeutic effects af-
ter acetaminophen-induced hepatotoxicity.—Hoga-
boam, C. M., Bone-Larson, C. L., Steinhauser, M. L.,
Lukacs, N. W., Colletti, L. M., Simpson, K. J.,
Strieter, R. M., Kunkel, S. L. Novel CXCR2-depen-
dent liver regenerative qualities of ELR-containing
CXC chemokines. FASEB J. 13, 1565–1574 (1999)
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The deleterious effects of accidental or inten-
tional (1) acetaminophen overdose often manifest
many hours after major hepatic injury has occurred.
When administered within 8 h (2), N-acetyl-cysteine
(NAC),2 a precursor of glutathione that is the stan-
dard medical treatment for acetaminophen overdose
cases, effectively inhibits liver injury and prevents
fulminant hepatic failure. However, because the
onset of symptoms of acetaminophen overdose may
be delayed or misinterpreted, the therapeutic win-
dow for NAC treatment of acetaminophen toxicity is
frequently missed (3). Despite advances in support-
ive care, acute hepatic failure attributed to acetamin-
ophen ingestion approaches 50% in the United
Kingdom (4). A liver transplant will ensure patient
survival in these cases (5), but the majority of pa-
tients affected by acetaminophen overdose do not
fulfill all the necessary criteria for liver transplanta-
tion because they lack co-existent renal failure or
severe acidosis (6). At present, considerable experi-
mental attention is directed at elucidating factors
that promote rapid and maximal liver regeneration
after exposure of the liver to toxic or mechanical
insults (7). Cytokines, particularly tumor necrosis
factor a (TNF-a) (8) and interleukin 6 (IL-6) (9),
are among newly described factors that possess
unique liver regenerative qualities. Additional stud-
ies have shown that elevations in TNF-a and IL-6 in
the damaged liver directly promote the de novo
generation of ELR-containing CXC chemokines
such as MIP-2 and ENA-78 (10, 11). These chemo-
kines have been shown to contribute to the inflam-
matory process that follows acute hepatic injury (12,
13), but their role during the liver regenerative
process remains largely unexplored. ELR-CXC che-
mokines are distinct from other CXC chemotactic
cytokines because these mediators contain three
amino acid residues, Glu-Leu-Arg (i.e., ELR), which
are immediately next to the CXC motif, and the
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majority of ELR-CXC chemokines bind to CXC
chemokine receptor 2 (CXCR2) (14).
Since ELR-CXC chemokines also exert mitogenic
effects on a number of structural-type cells (reviewed
in ref 15), we compared the therapeutic efficacy of
NAC and hepatocyte growth factor (HGF) (7) with
that of ELR-CXC chemokines in fasted mice chal-
lenged with acetaminophen. Superior therapeutic
effects of MIP-2 [an interleukin 8-related chemokine
present in rodents (16)], human IL-8, and ENA-78
were observed when any one of these ELR-CXC
chemokines was intravenously (i.v.) infused into
mice 10 h after acetaminophen challenge. Con-
versely, delayed NAC, IP-10 (a non-ELR-CXC chemo-
kine), or HGF treatment did not attenuate liver
injury in acetaminophen-challenged mice. It was also
apparent from in vitro experiments that ELR-CXC
chemokines had CXC receptor 2 (CXCR2) -depen-
dent mitogenic effects on cultured hepatocytes.
Taken together, these data suggest that ELR-CXC
chemokines can reverse acetaminophen-induced
liver injury and exert prominent therapeutic effects
when NAC treatment is ineffective against acetamin-
ophen-induced hepatotoxicity.
MATERIALS AND METHODS
Acetaminophen-induced hepatic injury
Female CD1 (6–8 wk of age) were purchased from Charles
River Laboratories (Portage, Mich.) and maintained under
specific pathogen-free conditions with free access to water
and food prior to each experiment. Fresh suspensions of
acetaminophen (Sigma Chemical Company, St. Louis, Mo.)
were made daily by dissolving the compound in phosphate-
buffered saline (PBS) warmed to 40°C. In all experiments,
mice were allowed free access to water alone prior to an
intraperitoneal (i.p.) injection of 400 mg/kg acetaminophen
as described previously (17).
Experimental protocols
In the first set of experiments, groups of fasted CD1 mice
were pretreated with preimmune rabbit serum or polyclonal
rabbit anti-mouse antibody directed against the ELR-CXC
chemokine receptor CXCR2; these mice were killed at 6, 48,
and 144 h after acetaminophen challenge for histological
examination of liver tissue. All polyclonal rabbit antibodies
were generated and screened to ensure specificity prior to use
as described previously in detail (18); the biological half-life
of these immunoneutralizing antibodies was ;36 h (10). The
anti-CXCR2 antibody inhibited KC-induced neutrophil influx
into the peritoneum of mice and the MIP-2- and KC-induced
angiogenesis in the rat cornea (R. M. Strieter, personal
communication). Additional groups of mice (n55–8 mice/
group) were pretreated with 0.5 ml of preimmune rabbit
serum or the same volume of polyclonal rabbit anti-mouse
MIP-2 antibody 2 h prior to acetaminophen challenge. Mice
were killed at 144 h after acetaminophen challenge and livers
were prepared for histological examination.
In the next set of experiments, mice were fasted for 12 h
and received one dose of NAC, murine MIP-2, and the human
proteins ENA-78, IL-8, HGF, or IP-10 either immediately or
10 h after acetaminophen challenge. Recombinant chemo-
kines and HGF were obtained from R&D Systems (Minneap-
olis, Minn.) or Pepro Tech (Rockyhill, N.J.); NAC was ob-
tained from Sigma. Mice were injected i.v. with 100 mg of
NAC or 2 mg of recombinant protein dissolved in 0.5 ml of
normal saline. All mice were subsequently killed 48 h after
acetaminophen challenge, and serum and liver samples were
removed.
In the final set of experiments, mice were fasted for 24 h
and received MIP-2 (2 mg) or NAC (100 mg) via an i.v.
injection either immediately or 10 h after acetaminophen
challenge; liver and serum samples were removed from
surviving mice 48 h after acetaminophen challenge. Liver and
serum samples from the experimental groups and from mice
challenged with an i.p. injection of PBS and treated i.v. with
normal saline were processed as described below.
Chemokine ELISAs
Immunoreactive levels of CC and CXC chemokines were
measured in liver homogenates using a modified double-
ligand enzyme-linked immunoassay (ELISA) procedure as
described in detail elsewhere (18). Before each ELISA, snap-
frozen liver samples were thawed on ice, weighed, and
homogenized in solution containing 2 mg of protease inhib-
itor (Complete; Boehringer Mannheim, Indianapolis, Ind.)
per milliliter of normal saline. Previous studies in this labo-
ratory have shown that Complete does not interfere with any
of the chemokine ELISAs (18). Cell-free supernatants from
the liver homogenates were loaded in duplicate onto 96-well
microtiter plates coated with the appropriate capture anti-
body and blocked with 2% bovine serum albumin in PBS.
Each ELISA consistently detected concentrations of chemo-
kines below 10 pg/ml, and the specificity of the polyclonal
detection and capture antibodies was confirmed prior to its
use in an ELISA. Chemokines levels in liver homogenates
were normalized to the weight of the liver sample assayed.
Serum aspartate aminotransferase
Acute hepatocellular injury results in elevated levels of aspar-
tate aminotransferase (AST). Serum levels of AST were deter-
mined 48 h after mice were challenged with acetaminophen
by Clinical Pathology at the University of Michigan Medical
School (Ann Arbor, Mich.) using standardized techniques.
Histology
For histological assessment of hepatic injury, liver tissues were
fixed in 4% paraformaldehyde for 24 h prior to routine
histological processing. A pathologist assessed hematoxylin-
and eosin-stained slides from acetaminophen-challenged
mice in a blinded manner. Separate scoring systems were
devised to indicate the area of liver necrosis and hemorrhage
and the extent of hepatic inflammation. Detailed histological
grading of hepatic injury, including area of liver necrosis and
hemorrhage, was determined at 48 h after acetaminophen
challenge. Hepatic inflammation was graded as absent, slight,
moderate, or prominent.
Cultured hepatocyte proliferation
The effects of chemokines, NAC, and HGF on hepatocyte
proliferation after a 24 h acetaminophen challenge were
examined using normal murine liver cells obtained from
American Type Culture Collection (ATCC CRL-1638;
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NmuLi). Hepatocytes were plated at a density of 1.0 3 105
cells/well in 6-well tissue culture plates and deprived of fetal
bovine serum supplementation for 36 h prior to an experi-
ment. Fasted hepatocytes were subsequently exposed to 2.5
mg/ml of acetaminophen and left untreated or were treated
with NAC, MIP-2, ENA-78, IL-8, IP-10, or HGF. NAC at 1 mM
or individual cytokines at 1 ng/ml were added either imme-
diately or 10 h after the addition of acetaminophen. In
additional in vitro experiments, normal serum or anti-CXCR2
antibody was also included in cultures of treated or untreated
hepatocytes exposed to PBS or acetaminophen. [3 H]thymi-
dine (10 mCi) was added to each well for the final 4 h of
culture; 24 h after the addition of acetaminophen, suspen-
sions of hepatocytes were prepared via cell lysis with 0.5%
(v/v) Triton-X100. [3H]thymidine incorporation was assessed
by liquid scintillation counting on a Beckman counter (Beck-
man Instruments, Fullerton, Calif.).
Statistical analysis
Results are expressed as means 6 standard error of the mean
(se) of 5–10 mice per group, and analysis of variance was used
to detect significant differences between means. All statistical
calculations were performed using GraphPad Prism 2.0 com-
puter software (San Diego, Calif.); P # 0.05 was considered
significant.
RESULTS
Endogenous CXCR2 and MIP-2 are required for
hepatic regeneration after acetaminophen
challenge
CXCR2 is the only CXC chemokine receptor that
binds ELR-CXC chemokines in the mouse (14, 19).
Thus, the role of endogenous CXCR2 in the hepa-
totoxic effects of acetaminophen was examined in
fasted mice that received either neutralizing rabbit
anti-mouse CXCR2 antibody or preimmune rabbit
serum 2 h prior to acetaminophen challenge. As
shown in Fig. 1, anti-CXCR2 antibody pretreatment
markedly enhanced the degree of liver hemorrhage
Figure 1. Histological appearance of liver in mice pretreated with either preimmune rabbit serum (A, C ) or rabbit anti-mouse
CXCR2 antibody (B, D) prior to acetaminophen challenge. Mice were fasted for 12 h and received preimmune serum or
anti-CXCR2 antibody 2 h prior to an i.p. challenge with 400 mg/kg of acetaminophen. Liver tissue was removed at 6 h (A, B)
and 48 h (C, D) after acetaminophen challenge. At both time points, profoundly greater hemorrhage and necrotic injury in the
liver was observed in anti-CXCR2 antibody-treated mice compared to that in mice that received preimmune serum prior to
acetaminophen challenge. Original magnification was 4003 for each photomicrograph and 403 for the inset photomicrograph.
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and necrosis at 6 h (Fig. 1B) and 48 h (Fig. 1D) after
acetaminophen challenge compared to acetamino-
phen-induced injury at 6 h (Fig. 1A) and 48 h (Fig.
1C) in preimmune serum-treated mice. Although
mice that received anti-CXCR2 antiserum alone did
not show liver injury at any time point, marked liver
necrosis was still apparent 6 days after acetamino-
phen challenge in mice that received anti-CXCR2
antibody (not shown). This was in marked contrast
to the restored liver histology at this time in mice
that received preimmune serum prior to acetamino-
phen challenge (not shown).
Endogenous hepatic levels of murine monocyte che-
moattractant protein-1 (MCP-1), macrophage inflam-
matory protein-1a (MIP-1a), MIP-2, and KC were de-
termined by ELISA (Table 1). KC is a murine ELR-
CXC chemokine with neutrophil chemotactic
properties (12) that binds CXCR2 with ;10-fold less
affinity than MIP-2 (19) The murine CC chemokines
MCP-1 and MIP-1a were unchanged in liver homoge-
nates from mice challenged 48 h earlier with 400
mg/kg of acetaminophen. In contrast, significant ele-
vations in the murine ELR-CXC chemokines MIP-2
and KC were present in the same liver homogenates.
Elucidation of the role of increased MIP-2 levels in
the liver was explored through the use of a poly-
clonal rabbit antibody directed against murine MIP-2
or preimmune rabbit serum to mice 2 h prior to
acetaminophen challenge. In mice that did not
receive acetaminophen, the presence of anti-MIP-2
antiserum or normal rabbit serum did not appear to
exert any discernible injurious effect on the liver
(not shown). Histological examination of liver sam-
ples on day 6 post-acetaminophen showed that en-
dogenous MIP-2 was critical for normal liver regen-
eration in the mouse after acetaminophen challenge
(Fig. 2). In contrast to mice that received preim-
mune serum (Fig. 2A), severe disruption of the
hepatic architecture around central veins was readily
apparent in mice that received anti-MIP-2 prior to
acetaminophen challenge 6 days previously (Fig.
2B). Areas of necrosis encompassing . 50% of the
total liver area were apparent in mice pretreated with
anti-MIP-2 antibody (see inset to Fig. 2B).
ELR-CXC chemokine vs. NAC therapy during
acetaminophen challenge
The therapeutic effects of ELR-CXC chemokines
were compared with those of NAC and HGF therapy
during experimental acetaminophen hepatotoxicity.
TABLE 1. Changes in hepatic levels of chemokines prior to and
48 h after acetaminophen challenge in mice
Chemokine
Prior to acetaminophena
(ng/g tissue)
48 h post acetaminophenb
(ng/g tissue)
MCP-1 1.0 6 0.1 0.9 6 0.3
MIP-1a 0.5 6 0.1 0.1 6 0.2
MIP-2 0.4 6 0.1 0.8 6 0.1‡
KC 0.4 6 0.1 0.9 6 0.2*
a Mice were fasted for 12 h prior to liver removal. Tissue samples
were homogenized and supernatants were analyzed using ELISA.
Data are mean 6 se of four representative experiments.
b Mice were fasted for 12 h prior to receiving an intraperitoneal
injection of 400 mg/kg acetaminophen. Forty-eight hours later, liver
was removed and prepared for ELISA. Data are mean 6 se of four
representative experiments.
‡ P 5 0.047 compared to levels in liver removed prior to
acetaminophen.
* P 5 0.033 compared to levels in liver removed prior to
acetaminophen.
Figure 2. Histological appearance of livers from mice pretreated with preimmune serum (A) or polyclonal rabbit antibodies
against murine MIP-2 (B). Mice were fasted for 12 h and received preimmune serum or neutralizing polyclonal antibody 2 h
prior to i.p. injection with 400 mg/kg of acetaminophen. Mice were allowed free access to food after these treatments; 6 days
later the liver was removed from each mouse for routine histological processing. Histological injury was absent in liver tissue
removed from mice that received preimmune rabbit serum (A). Mice that received anti-MIP-2 antibody exhibited centrilobular
hepatic injury and inflammation, and major areas of necrosis and hemorrhage were also apparent in the liver (see inset for B).
Original magnification was 4003 for the main photomicrographs and 403 for the inset photomicrograph.
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In untreated CD1 mice, the mean serum AST level
was increased ;20–fold above the baseline value of
99 6 34 IU/l at 48 h after acetaminophen challenge
(Fig. 3A, B). Among the treatments used immedi-
ately after acetaminophen challenge, NAC treatment
reduced AST levels by ;90% (Fig. 3A). In addition,
all three ELR-CXC chemokines (one mouse and two
human) significantly reduced serum AST levels by
;50%, but IP-10 (a non-ELR CXC chemokine) and
HGF did not lower serum AST levels in acetamino-
phen-challenged mice. When treatment was delayed
10 h after acetaminophen challenge, MIP-2, ENA-78,
and IL-8, but neither IP-10 nor NAC, significantly
reduced serum AST levels (Fig. 3B).
The hepatic injury observed at 10 h (not shown)
and 48 h (representative liver histology shown in
Fig. 4) after acetaminophen challenge was charac-
terized by intense necrosis and hemorrhage local-
ized around central veins in the liver. In untreated
mice, greater than 50% of the total liver mass was
necrotic and exhibited hemorrhage (Fig. 4A).
Marked attenuation of liver injury was observed in
mice that received 2 mg of MIP-2 (Fig. 4B), ENA-78
(Fig. 4C), or IL-8 (Fig. 4D), but not IP-10 (Fig. 4E),
HGF (Fig. 4F), or 100 mg of NAC (Fig. 4G), when
these treatments were delayed until 10 h after
acetaminophen challenge. The beneficial effects
of delayed MIP-2, ENA-78, and IL-8 therapy were
most marked around hepatic central veins, where
healthy hepatocytes were readily apparent (Fig.
4B–D), and the histological appearance of liver
sections in these treatment groups was similar to
that observed in normal mice (Fig. 4H). In addi-
tion, necrotic injury in acetaminophen-challenged
mice treated with ELR-CXC chemokines was either
absent or comprised less than 10% of the liver
area.
Delayed MIP-2 therapy protects mice from the
lethal effects of acetaminophen
The lethal effects of a 400 mg/kg dose of acetamin-
ophen were evident when mice were fasted for a
longer period. In these experiments, only 25% of
mice fasted for 24 h prior to acetaminophen chal-
lenge survived until day 2 (Table 2). NAC treatment
of mice immediately after acetaminophen challenge
increased mouse survival to 90%, whereas MIP-2
given at the same time spared ;50% of mice. When
NAC treatment was delayed by 10 h after acetamin-
ophen challenge, the survival rate in this group of
mice was significantly reduced to 25%. However,
60% of mice that received a similarly delayed treat-
ment of MIP-2 were protected from the lethal effects
of acetaminophen (Table 2).
Mice that received NAC immediately after acet-
aminophen challenge had significantly lower lev-
els of serum AST levels than mice that received
MIP-2 at this time (Fig. 5). The converse was
observed when the NAC and MIP-2 treatments
were delayed for 10 h after acetaminophen chal-
lenge. Accordingly, mice in the delayed MIP-2
treatment group had significantly lower levels of
serum AST compared to mice that received the
delayed NAC treatment.
The histological appearance of liver tissue re-
moved from these groups of mice corroborated
the changes in serum AST. As shown in Fig. 6, the
delivery of NAC to mice immediately after (Fig.
6A) but not 10 h post (Fig. 6B) acetaminophen
Figure 3. Serum aspartate aminotransferase (AST) activity in mice treated immediately after (A) or 10 h post (B)
acetaminophen challenge. Mice were fasted for 12 h prior to i.p. injection with 400 mg/kg of acetaminophen and then
allowed free access to food. 48 h later, blood was removed from each mouse for AST determination. When administered
immediately after acetaminophen challenge, NAC was most effective at reducing AST levels compared to the other
treatments. In addition, AST levels were significantly reduced in mice that received MIP-2, ENA-78, or IL-8, but not IP-10
or HGF (A). In contrast, when therapeutic intervention was delayed 10 h after acetaminophen challenge, only MIP-2,
ENA-78, and IL-8 significantly reduced serum AST levels (B). Data are means 6 se of four separate experiments (n55
mice/group); *P # 0.05 compared to control.
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markedly reduced liver injury. Although mice that
received MIP-2 immediately after acetaminophen
challenge exhibited marked liver injury at the 48 h
time point (Fig. 6C), the liver appearance in mice
that received the delayed MIP-2 therapy was mark-
edly improved at this time point (Fig. 6D). Taken
together, these findings suggested that when given
immediately after a lethal dose of acetaminophen,
NAC was clearly superior to MIP-2 treatment.
However, delayed MIP-2 therapy was clearly more
beneficial compared with a delayed NAC therapy
as evidenced by reduced mouse mortality, serum
AST, and liver injury in the delayed ELR-CXC
chemokine therapy group.
ELR-CXC chemokines maintain hepatocyte
proliferation via CXCR2
The liver-regenerative properties of ELR-CXC che-
mokines were also explored in vitro using a normal
hepatocyte cell line. Untreated liver cells were
susceptible to the toxic effects of acetaminophen
as evidenced by significantly decreased cell prolif-
eration (as monitored by [3H]thymidine incorpo-
Figure 4. Histological appearance of livers from mice that
were challenged with acetaminophen and received normal
saline (A) or 2 mg of the following chemokines: murine
MIP-2 (B), human ENA-78 (C ), human IL-8 (D), human
IP-10 (E ), human HGF (F ). Liver histology was taken from
mice that received 100 mg of N-acetylcysteine (G ). Mice
were fasted for 12 h prior to i.p. injection with 400 mg/kg
of acetaminophen, then allowed free access to food. In
these experiments, however, saline, chemokines, or NAC
were given by i.v. injection 10 h after acetaminophen
challenge, and the liver was removed from each mouse for
histological examination at the 48 h time point after
acetaminophen. When treatment was delayed for 10 h, only
mice that received MIP-2 (B ), ENA-78 (C ), or IL-8 (D)
showed any major histological improvement, particularly in
the centrilobular regions most sensitive to the hepatotoxic
effects of acetaminophen. (H) Liver histology from a
normal mouse. Original magnification was 4003 for each
photomicrograph.
TABLE 2. Percent survival in CD1 mice fasted for 24 h and
challenged with 400 mg/kg of acetaminophen
Treatment
Immediately after
acetaminophena 10 h post acetaminophenb
Saline 25 25
NAC 90* 20
MIP-2 50* 60*
a Groups of n 5 12 (saline), 13 (NAC), and 15 (MIP-2) mice
were fasted for 24 h, challenged i.p. with 400 mg/kg acetaminophen,
and immediately thereafter received 0.5 ml of saline, NAC or MIP-2
through i.v. injection. Survival was monitored over the subsequent
48 h.
b Groups of n 5 12 (saline), 13 (NAC), and 10 (MIP-2) mice
were fasted for 24 h, challenged i.p. with 400 mg/kg acetaminophen,
and 10 h thereafter received 0.5 ml of saline, NAC, or MIP-2 through
i.v. injection. Forty-eight hours later, liver was removed and prepared
for ELISA.
* P # 0.05 compared with saline control.
Figure 5. Serum aspartate aminotransferase (AST) activity in
mice fasted for 24 h prior to MIP-2 or NAC treatment
immediately after or 10 h after a 400 mg/kg acetaminophen
challenge. Blood was removed from each mouse 48 h after
acetaminophen challenge for AST determination. When ad-
ministered immediately after acetaminophen challenge, NAC
was more effective than MIP-2 at reducing AST levels. How-
ever, when the intervention was delayed 10 h, MIP-2 treat-
ment was more effective than NAC treatment in the reduction
of acetaminophen induced elevations in serum AST. Data are
means 6 se of groups of 5 mice; *P # 0.05 compared to
control.
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ration) after exposure to acetaminophen for 24 h
(Fig. 7A, B). Although NAC did not alter the
proliferation of liver cells exposed to PBS, the
addition of NAC to liver cell cultures immediately
after acetaminophen maintained the proliferation
of these cells at levels measured in cell cultures
challenged with PBS (Fig. 7A). Likewise, MIP-2,
ENA-78, IL-8 and HGF did not change the prolif-
eration of liver cells exposed to PBS, but MIP-2
and ENA-78 prevented the drop in liver cell pro-
liferation after exposure to acetaminophen for
24 h. The non-ELR CXC chemokine IP-10, which
binds CXCR3, lowered the proliferation rate of
liver cells exposed to PBS by 40% compared to
control cultures with PBS, but the proliferative
response of liver cells was not further reduced by
the exposure of these cells to acetaminophen. A
10 h delay in the treatment of the liver cells after
acetaminophen challenge significantly reduced
liver cell proliferation in cultures treated with
NAC compared to the respective PBS control
cultures (Fig. 7B). In contrast, all other cultures of
liver cells exposed to acetaminophen that received
delayed cytokine or chemokine treatment showed
[3H]thymidine incorporation comparable to cyto-
kine- or chemokine-treated cultures exposed to
PBS.
The mitogenic properties of ELR-CXC chemo-
kines were also dependent on their ability to bind to
CXCR2, since the presence of a rabbit anti-mouse
CXCR2 antibody significantly reduced the mitogenic
effects of MIP-2, ENA-78, and IL-8 on acetamino-
phen-challenged liver cells (Fig. 8). The presence of
anti-CXCR2 antibody also significantly reduced
[3H]thymidine incorporation by NAC-treated liver
cells exposed to acetaminophen for 24 h. However,
the mitogenic effects of IP-10 and HGF on acetamin-
ophen-challenged liver cells were independent of
Figure 6. Histological appearance of livers from mice that were challenged with acetaminophen and received 100 mg of
NAC (A, B) or 2 mg of murine MIP-2 (C, D) by i.v. injection either immediately after or 10 h later. Mice were fasted for
24 h prior to i.p. injection with 400 mg/kg of acetaminophen and then allowed free access to food. 48 h later, the liver
was removed from each mouse for histological examination. When given immediately after acetaminophen, NAC
treatment (A) provided superior hepatic protection to MIP-2 treatment (C ). The delayed administration of NAC did not
attenuate hepatic injury in acetaminophen-challenged mice, but mice that received MIP-2 at this time showed major
restoration in the centrilobular regions most sensitive to acetaminophen. Original magnification was 4003 for each
photomicrograph.
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CXCR2 function. Overall, these in vitro data sug-
gested that CXC chemokines possess hepatoprotec-
tive effects after acetaminophen challenge due partly
to their CXCR2-dependent mitogenic effects on liver
resident cells.
DISCUSSION
Acetaminophen is a widely used analgesic and anti-
pyretic medication that is generally perceived to be
nontoxic. However, large or repeated doses of acet-
aminophen cause profound liver injury (1), poten-
tially leading to liver failure (20). Because the symp-
toms of acetaminophen overdose commonly mimic
common illnesses, the real diagnosis and the initia-
tion of NAC therapy may be delayed beyond the time
in which NAC effectively reduces liver injury (21).
After the therapeutic window of NAC is passed, liver
transplantation is often the only clinical intervention
that will ensure the survival of these patients. Unfor-
tunately, liver transplant recipients require intensive
management to avoid potential complications due to
rejection of the hepatic transplant (22). A novel
therapeutic strategy that reduces the need for liver
transplantation after acetaminophen overdose may
be found in the inherent regenerative processes of
the liver (23). Despite evidence that the liver pos-
sesses a tremendous capacity to regenerate after
hepatic injury, few biological substances have been
identified that, when delivered several hours after
liver injury has occurred, promote a rapid hepato-
cyte proliferative response to counteract the pro-
found hepatic necrosis that follows acetaminophen-
induced toxicity.
Centrilobular hepatocytes have the important
role of metabolizing many of the drugs introduced
into the liver (24). When exposed to acetamino-
phen, the hepatocyte uses glutathione to neutral-
ize the toxic effects of the primary metabolite of
acetaminophen, N-acetyl-p-benzoquinoneimine.
The toxic effects of this metabolite can be reversed
with the addition of NAC, but the efficacy of this
compound declines precipitously as hepatocytes
Figure 7. Proliferation of cultured liver cells exposed to saline (control), NAC, MIP-2, ENA-78, IL-8, IP-10, or HGF in the
presence or absence of acetaminophen. Liver cells were treated with NAC (1 mM), cytokines, or chemokines (all at 1 ng/ml)
either immediately after (A) or 10 h after (B) the addition of PBS or acetaminophen (2.5 mg/ml). 4 h before the end of a 24 h
exposure of the liver cells to PBS or acetaminophen, cultures were pulsed with 10 mCi of [3H]thymidine/well and
[3H]thymidine incorporation was determined by liquid scintillation counting. Data are mean 6 se of three separate
experiments. *P # 0.05 compared to respective cultures of hepatocytes that received NAC or cytokine treatment alone. APAP:
acetaminophen.
Figure 8. Role of CXCR2 in the mitogenic effects of saline
(control), NAC, MIP-2, ENA-78, IL-8, IP-10, or HGF in
cultures of acetaminophen-challenged liver cells. Liver cells
were deprived of serum for 36 h prior to exposure to
acetaminophen (2.5 mg/ml); NAC (1 mM), cytokine, or
chemokine (all at 1 ng/ml) were added 10 h later. Rabbit
preimmune serum or rabbit anti-mouse CXCR2 antibody was
added concomitantly with NAC, cytokine, or chemokine
treatment. 4 h before the conclusion of a 24 h exposure of the
liver cells to PBS or acetaminophen, cultures were pulsed with
10 mCi of [3H]thymidine/well; [3H]thymidine incorporation
was determined by liquid scintillation counting. Acetamino-
phen is abbreviated to APAP. Data are mean 6 se of three
separate experiments.
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succumb to the toxic effects of N-acetyl-p-benzo-
quinoneimine. Delayed NAC treatment for acet-
aminophen-induced hepatotoxicity fails, in part,
because this drug fails to trigger the restoration of
the critical mass of hepatocytes needed for liver
function. This was confirmed in the present study
by the failure of delayed NAC treatment to prevent
acetaminophen-induced liver damage observed in
vivo and the decreased liver cell proliferation
observed in vitro after acetaminophen challenge.
Consequently, at the latter stages of drug-induced
hepatotoxicity, the proliferation of the normally
quiescent hepatocyte is paramount to prevent ful-
minant hepatic failure (23). However, many of the
factors that promote the proliferation of cultured
hepatocytes do not necessarily exhibit liver regen-
erative effects in vivo (7). The in vitro data pre-
sented herein showed that ELR-CXC chemokines,
HGF, and IP-10 effectively maintained hepatocyte
proliferation in the presence of toxic levels of
acetaminophen. More important, the mitogenic
effect of these factors was still evident when these
mediators were added to hepatocytes with prior
exposure to acetaminophen for 10 h. However,
unlike the ELR-CXC chemokines, neither the im-
mediate or delayed injection of HGF or IP-10 into
acetaminophen-challenged mice promoted rapid
liver restoration after acetaminophen-induced in-
jury. Thus, these data demonstrate that ELR-CXC
chemokines possess novel hepatic regenerative
properties that were consistently observed during
in vivo and in vitro acetaminophen challenge of
hepatic tissue.
CXC chemokines are widely recognized as inflam-
matory cell recruitment factors (15). Nevertheless,
the list of functions attributable to CXC chemokines
has recently expanded and newer biological effects
of these mediators include angiogenesis (25) and
mitogenesis (16). In particular, the newly described
properties of ELR-CXC chemokines are attributed
mainly to the ELR motif (25, 26). ELR-CXC chemo-
kines are specific for CXCR1 and CXCR2, whereas
the non-ELR-CXC chemokines (that lack angiogenic
and mitogenic effects) typically bind to CXCR3 and
CXCR4. Several lines of evidence suggest that ELR-
CXC chemokines may by critical participants in
generalized wound healing responses. First, elevated
levels of ELR-CXC chemokines and CXCR2 are
invariably found in damaged tissues, including the
liver (27) and skin (28). Second, ELR-CXC chemo-
kines have previously been shown to have potent
mitogenic effects on several tissue resident cells,
including keratinocytes (29), epithelial cells (16),
endothelial cells (30), and hepatocytes (11). Third,
many of the previously mentioned cells exhibit de
novo synthesis of ELR-CXC chemokines after inflam-
matory stimuli. For example, hepatocytes (31) and
hepatic stellate cells (13) have been shown to gener-
ate ELR-CXC chemokines after exposure to acet-
aminophen or other inflammatory stimuli. Liver
injury precipitated by hepatectomy is also associated
with dramatic increases in MIP-2 and ENA-78 (10),
the absence of which after antibody-mediated immu-
noneutralization significantly impairs normal liver
regeneration (11). The precise cellular mechanism
by which ELR-CXC chemokines facilitate hepatocyte
proliferation is being investigated. Thus, the novel
hepatocyte regenerative properties of ELR-CXC che-
mokines may represent another viable therapeutic
intervention in the acetaminophen-damaged liver
that may obviate or postpone the need for liver
transplantation.
CONCLUSION
We have identified ELR-CXC chemokines that
possess therapeutic properties in the acutely dam-
aged liver after acetaminophen challenge. The
data shown herein suggest that ELR-containing
CXC chemokines promote rapid liver regenera-
tion after drug-induced acute injury. Overall, ELR-
CXC chemokines such as human IL-8 and ENA-78
may have tremendous clinical potential in reduc-
ing the need for liver transplantation and the
mortality associated with acetaminophen-induced
fulminant liver failure.
This work was supported by National Institutes of Health
grants 1P50HL56402, 1P50HL60289, CA66180, HL35276,
HL31963, and AI36302. K.J.S. was supported in part by the
Medical Research Council of the United Kingdom and by
Scottish Hospital Research Trust (no. 1512).
REFERENCES
1. Makin, A. J., and Williams, R. (1997) Acetaminophen-induced
hepatotoxicity: predisposing factors and treatments. Adv. Intern.
Med. 42, 453–483
2. De Groote, J., and Van Steenbergen, W. (1995) Paracetamol
intoxication and N-acetyl-cysteine treatment. Acta Gastroenterol.
Belgium 58, 326–334
3. Delanty, N., and Fitzgerald, D. J. (1996) Paracetamol poisoning:
the action line and the timing of acetylcysteine therapy. Irish
Med. J. 89, 156–158
4. Atillasoy, E., and Berk, P. D. (1995) Fulminant hepatic failure:
pathophysiology, treatment, and survival. Annu. Rev. Med. 46,
181–191
5. Bernal, W., Wendon, J., Rela, M., Heaton, N., and Williams, R.
(1998) Use and outcome of liver transplantation in acetamino-
phen-induced acute liver failure. Hepatology 27, 1050–1055
6. Riordan, S. M., and Williams, R. (1999) Cause and prognosis in
acute liver failure. Liver Transpl. Surg. 5, 86–89
7. Fausto, N., Laird, A. D., and Webber, E. M. (1995) Liver
regeneration. 2. Role of growth factors and cytokines in hepatic
regeneration. FASEB J. 9, 1527–1536
8. Yamada, Y., Kirillova, I., Peschon, J. J., and Fausto, N. (1997)
Initiation of liver growth by tumor necrosis factor: deficient liver
regeneration in mice lacking type I tumor necrosis factor
receptor. Proc. Natl. Acad. Sci. USA 94, 1441–1446
1573ELR-CXC CHEMOKINES REVERSE ACUTE HEPATIC INJURY
9. Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto,
G., Furth, E. E., Poli, V., and Taub, R. (1996) Liver failure and
defective hepatocyte regeneration in interleukin-6-deficient
mice. Science 274, 1379–1383
10. Colletti, L. M., Kunkel, S. L., Green, M., Burdick, M., and
Strieter, R. M. (1996) Hepatic inflammation following 70%
hepatectomy may be related to up- regulation of epithelial
neutrophil activating protein-78. Shock 6, 397–402
11. Colletti, L. M., Green, M., Burdick, M. D., Kunkel, S. L., and
Strieter, R. M. (1998) Proliferative effects of CXC chemokines in
rat hepatocytes in vitro and in vivo. Shock 10, 248–257
12. Lentsch, A. B., Yoshidome, H., Cheadle, W. G., Miller, F. N., and
Edwards, M. J. (1998) Chemokine involvement in hepatic
ischemia/reperfusion injury in mice: roles for macrophage
inflammatory protein-2 and KC [corrected and republished
article originally printed in Hepatology 1998 Feb; 27: 507–512].
Hepatology 27, 1172–1177
13. Sprenger, H., Kaufmann, A., Garn, H., Lahme, B., Gemsa, D.,
and Gressner, A. M. (1997) Induction of neutrophil-attracting
chemokines in transforming rat hepatic stellate cells. Gastroen-
terology 113, 277–285
14. Cacalano, G., Lee, J., Kikly, K., Ryan, A. M., Pitts-Meek, S.,
Hulgren, B., Wood, W. I., and Moore, M. W. (1994) Neutrophil
and B cell expansion in mice that lack the murine IL-8 receptor
homolog. Science 265, 682–684
15. Strieter, R. M., Standiford, T. J., Huffnagle, G. B., Colletti, L. M.,
Lukacs, N. W., and Kunkel, S. L. (1996) “The good, the bad, and
the ugly.” The role of chemokines in models of human disease.
J. Immunol. 156, 3583–3586
16. Driscoll, K. E., Hassenbein, D. G., Howard, B. W., Isfort, R. J.,
Cody, D., Tindal, M. H., Suchanek, M., and Carter, J. M. (1995)
Cloning, expression, and functional characterization of rat
MIP-2: a neutrophil chemoattractant and epithelial cell mito-
gen. J. Leukoc. Biol. 58, 359–364
17. Manautou, J. E., Tveit, A., Hoivik, D. J., Khairallah, E. A., and
Cohen, S. D. (1996) Protection by clofibrate against acet-
aminophen hepatotoxicity in male CD-1 mice is associated
with an early increase in biliary concentration of acetamino-
phen-glutathione adducts. Toxicol. Appl. Pharmacol. 140,
30 –38
18. Evanoff, H., Burdick, M. D., Moore, S. A., Kunkel, S. L., and
Strieter, R. M. (1992) A sensitive ELISA for the detection of
human monocyte chemoattractant protein-1 (MCP-1). Immunol.
Invest. 21, 39–49
19. Lee, J., Cacalano, G., Camerato, T., Toy, K., Moore, M. W.,
and Wood, W. I. (1995) Chemokine binding and activities
mediated by the mouse IL-8 receptor. J. Immunol. 155,
2158 –2164
20. Heubi, J. E., Barbacci, M. B., and Zimmerman, H. J. (1998)
Therapeutic misadventures with acetaminophen: hepatotoxicity
after multiple doses in children. J. Pediatr. 132, 22–27
21. Casey, P. B., and Tracey, J. A. (1997) N-acetylcysteine (NAC)–a
safe antidote in paracetamol poisoning? Irish Med. J. 90, 38
22. Rosen, H. R., Shackleton, C. R., and Martin, P. (1996) Indica-
tions for and timing of liver transplantation. Med. Clin. N. Am.
80, 1069–1102
23. Kay, M. A., and Fausto, N. (1997) Liver regeneration: prospects
for therapy based on new technologies. Mol. Med. Today 3,
108–115
24. Farrell, G. C. (1997) Drug-induced hepatic injury. J. Gastroen-
terol. Hepatol. 12, S242—S250
25. Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A.,
Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A.,
Marriott, D., Chan, S. Y., Roczniak, S., and Shanafelt, A. B.
(1995) The functional role of the ELR motif in CXC
chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348–
27357
26. Clark-Lewis, I., Dewald, B., Geiser, T., Moser, B., and Baggio-
lini, M. (1993) Platelet factor-4 binds to interleukin-8
receptors and activates neutrophils when its N-terminus is
modified with Glu-Leu-Arg. Proc. Natl. Acad. Sci. USA 90,
3574 –3577
27. Sheron, N., Bird, G., Koskinas, J., Portmann, B., Ceska, M., and
Lindley, I. (1993) Circulating and tissue levels of neutrophil
chemotaxis interleukin-8 are elevated in severe acute alcoholic
hepatitis, and tissue levels correlate with neutrophil infiltration.
Hepatology 18, 41–46
28. Kulke, R., Bornscheuer, E., Schluter, C., Bartels, J., Rowert, J.,
Sticherling, M., and Christophers, E. (1998) The CXC receptor
2 is overexpressed in psoriatic epidermis. J. Invest. Dermatol. 110,
90–94
29. Michel, G., Kemeny, L., Peter, R., Beetz, A., Ried, C., Aren-
berger, P., and Ruzicka, T. (1992) Interleukin-8 receptor-
mediated chemotaxis of normal human epidermal cells. FEBS
Lett. 305, 241–243
30. Strieter, R. M., Polverini, P. J., Arenberg, D. A., and Kunkel, S. L.
(1995) The role of CXC chemokines as regulators of angiogen-
esis. Shock 4, 155–160
31. Takada, H., Mawet, E., Shiratori, Y., Hikiba, Y., Nakata, R.,
Yoshida, H., Okano, K., Kamii, K., and Omata, M. (1995)
Chemotactic factors released from hepatocytes exposed to acet-
aminophen. Dig. Dis. Sci. 40, 1831–1836
Received for publication January 11, 1999.
Revised for publication March 30, 1999.
1574 Vol. 13 September 1999 HOGABOAM ET AL.The FASEB Journal
